Stem Cell Therapeutic and Research Reauthorization Act of 2025
Summary
The Stem Cell Therapeutic and Research Reauthorization Act of 2025 seeks to reauthorize and amend the Stem Cell Therapeutic and Research Act of 2005. It primarily focuses on extending the C.W. Bill Young Cell Transplantation Program and the Cord Blood Inventory program.
The bill proposes to allocate $33,009,000 for each fiscal year from 2027 through 2031 to the C.W. Bill Young Cell Transplantation Program. It also extends the Cord Blood Inventory program through 2031.
This reauthorization aims to continue and enhance research and therapeutic applications related to stem cell transplantation and cord blood, potentially benefiting patients with various diseases.
Expected Effects
The primary effect of this bill will be the continued funding and operation of stem cell research and transplantation programs. This includes maintaining the cord blood inventory and supporting the C.W. Bill Young Cell Transplantation Program.
By extending these programs, the bill aims to facilitate ongoing research and treatment options for diseases treatable with stem cell therapies. This could lead to advancements in medical treatments and improved patient outcomes.
The reauthorization provides financial stability for these programs, allowing for long-term planning and sustained efforts in stem cell research and therapeutic applications.
Potential Benefits
- Continued funding for stem cell research and transplantation programs.
- Potential for advancements in medical treatments for various diseases.
- Improved patient access to stem cell therapies.
- Enhanced cord blood inventory for research and transplantation purposes.
- Long-term stability for research programs, enabling sustained efforts.
Most Benefited Areas:
Potential Disadvantages
- The bill does not address ethical concerns surrounding stem cell research, which may be a concern for some individuals.
- The increased funding may require reallocation of resources from other areas of the budget.
- The bill focuses primarily on reauthorization and funding, with limited provisions for addressing potential inefficiencies in existing programs.
- There may be concerns about the effectiveness of the programs in achieving their intended goals.
- The bill does not include specific provisions for ensuring equitable access to stem cell therapies for all populations.
Constitutional Alignment
The bill appears to align with the Constitution's general welfare clause (Preamble) by promoting public health through stem cell research and therapeutic applications. Congress has the power to appropriate funds for programs that it believes will promote the general welfare of the United States.
Article I, Section 8 grants Congress the power to collect taxes and appropriate funds for the general welfare. This bill falls under that power as it allocates funding for specific programs.
However, the Constitution does not explicitly address stem cell research, so the alignment is based on the interpretation of the general welfare clause and the power of Congress to allocate funds.
Impact Assessment: Things You Care About ⓘ
This action has been evaluated across 19 key areas that matter to you. Scores range from 1 (highly disadvantageous) to 5 (highly beneficial).